Literature DB >> 15715581

Unilateral optic neuropathy associated with sildenafil intake.

Nicolai Gruhn, Hans C Fledelius.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15715581     DOI: 10.1111/j.1600-0420.2005.00374.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


× No keyword cloud information.
  8 in total

Review 1.  Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.

Authors:  Alan M Laties
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 2.  Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?

Authors:  Helen V Danesh-Meyer; Leonard A Levin
Journal:  Br J Ophthalmol       Date:  2007-11       Impact factor: 4.638

3.  Post-marketing surveillance of ischaemic optic neuropathy in male veterans co-prescribed phosphodiesterase-5 inhibitors with organic nitrates or alpha-blockers.

Authors:  Dustin D French; Curtis E Margo
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 4.  Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link?

Authors:  Konstantinos Hatzimouratidis
Journal:  Curr Urol Rep       Date:  2007-11       Impact factor: 3.092

5.  Bilateral simultaneous anterior ischemic optic neuropathy associated with sildenafil.

Authors:  Marilita M Moschos; Ioannis Margetis
Journal:  Case Rep Ophthalmol       Date:  2011-08-18

6.  Bilateral Sequential Non-arteritic Anterior Ischemic Optic Neuropathy (NAION).

Authors:  Wang Shir Yen; Sugumar Yathavan; Muhamad Amin Ramli; Foo Siu Wan; Jemaima Che Hamzah
Journal:  Cureus       Date:  2021-11-09

Review 7.  Non-Arteritic Anterior Ischemic Optic Neuropathy Associated With the Use of Phosphodiesterase Type 5 Inhibitors: A Literature Review.

Authors:  Mosab Hor; Ahmed M Baradeiya; Hodan Qasim; Mohamed Nasr; Amad Mohammad
Journal:  Cureus       Date:  2022-08-03

Review 8.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.